For the twelve months ended Mar 31, 2026, Marker Therapeutics Inc. reported $3.95M of revenue and -$10.90M of net income.
MRKR revenueQ1 2026$751.7K
- Quarter YoY
- +115.3%
- QoQ
- -31.9%
- FY YoY
- -46.2%
- 5Y CAGR
- +48.0%
MRKR revenue was $751.7K in fiscal Q1 2026 (ended Mar 31, 2026), up 115.3% from a year earlier and down 31.9% from the prior quarter. For the full fiscal 2025 it was $3.55M, down 46.2% from fiscal 2024. Compound annual growth was +48.0% over 5 years. It rose in 6 of the last 8 fiscal years.
MRKR net incomeQ2 2026-$1.83M
MRKR net income was -$1.83M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$4.02M a year earlier. For the full fiscal 2025 it was -$12.16M, compared with -$10.73M in fiscal 2024.
MRKR EPSQ2 2026-$0.09
MRKR diluted EPS was -$0.09 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.29 a year earlier. For the full fiscal 2025 it was -$0.79.
Source: XBRL data Marker Therapeutics Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-12, first reported Nov 4, 2016; 1-for-10, first reported Mar 22, 2023.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.